Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Genus plc is a public limited company specializing in animal genetics, pioneering genetic improvement to help farmers produce high-quality milk and meat more efficiently and sustainably. Through its two main business units, ABS for dairy and beef cattle and PIC for pigs, it develops genetically superior breeding animals using cutting-edge technologies like genomic selection, DNA analysis, and advanced reproductive methods such as IVF and semen sexing. These innovations enable traits like feed efficiency, disease resistance, and faster growth, reducing resource use and greenhouse gas emissions while enhancing animal health and productivity. Genus plc serves over 50,000 customers in more than 85 countries with elite herds, semen, embryos, and on-farm services, often under multi-year royalty agreements priced by genetic merit indices. Employing nearly 3,500 people, including over 100 PhDs, and investing over 20 million GBP annually in R&D, the company operates a global supply chain from production facilities worldwide. Its proprietary technology platform and long-term partnerships create barriers to entry, positioning it as a leader in making nutritious animal protein more affordable and sustainable to nourish a growing world population.
£22.90
£0.22 (-0.95%)
EOD Jul 3, 2026
Operating margin is thin at 6.30%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue growth slowed to 0.6%, essentially flat. This is a business that needs a catalyst.
At 93x earnings, the current multiple leaves limited room for execution misses or growth deceleration. Net debt of £218M represents 4.5x FCF, leverage limits flexibility.
93.1x earnings, 31.1x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
£673M
▲ +0.6% YoY
Net Income (TTM)
£19M
▲ +704.2% YoY
Op. Margin
6.30%
▲ +5.3pp YoY
ROIC
4.33%
▲ +3.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
£49M
▲ +852.9% YoY
Op. Cash Flow (TTM)
£64M
▲ +66.7% YoY
Net Debt
£218M
Cash & Equiv.
£48M
3Y CAGR: +4.3%
Continue Research
At a P/E of 93.1 and a price-to-free-cash-flow of 31.1, Genus (GNS.XLON) trades above a two-stage DCF intrinsic value of about £14.62 per share, so at £22.90 the stock looks overvalued (36.2% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Genus scores 39/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 1.4%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about £14.62 per share for GNS.XLON, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around £10.97. At today's £22.90, that puts the stock about 36.2% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Genus scores 39 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 6.3% operating margin and a 4.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Genus pays a regular dividend of about £0.32 per share per year (typically in quarterly installments), a yield of roughly 1.4% at the current price. That is a payout ratio of about 109.3% of earnings, so the dividend is stretched at this level. Genus has grown the dividend at roughly 2.0% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For GNS.XLON's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. GNS.XLON currently trades above its estimated intrinsic value and scores 39/100 on quality (lower-quality). It also yields about 1.4%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.